IDEXX Laboratories Announces First Customer Deliveries of SNAPshot Dx™ Analyzer
The SNAPshot Dx Analyzer augments the IDEXX VetLab® Suite's ability to run a full profile within minutes by testing for T4 with either plasma or serum samples. Practices are able to screen and, when needed, determine treatment plans before patients leave the clinic, offering pet owners convenience and peace of mind. SNAPshot Dx runs multiple samples simultaneously for better throughput and efficient workflow. Activated SNAP® ELISA tests are simply inserted into either of two ports and the analyzer runs the assay, reads the results and, through the IDEXX VetLab® Station, automatically downloads the data into the patient's record. The results are then incorporated into the IDEXX VetLab Station's easy-to-read integrated diagnostic report for a complete picture of the patient's health.
"Along with the added convenience of T4 testing using plasma, SNAPshot Dx can run multiple patient samples simultaneously, delivering accurate, more comprehensive results in just minutes, benefitting both the practice and the patient," said Michael Lane, Director, IDEXX Chemistry Instrumentation. "This is the third new instrument added to the IDEXX VetLab Suite of in-house analyzers over the past four months," added Lane. The other two additions include the Catalyst Dx™ Chemistry Analyzer, which began shipping at the same time as the SNAPshot Dx Analyzer, and the IDEXX Coag Dx™ Analyzer, which was introduced in December 2007. These innovations continue the IDEXX tradition of offering IDEXX VetLab Suite upgrades that give veterinarians a full range of in-house diagnostic capabilities with rapid, integrated results and excellent workflow efficiencies.
Later in 2008, IDEXX plans to expand the SNAPshot Dx Analyzer’s test menu by adding the ability to run the entire family of SNAP® tests, which includes SNAP® FIV/FeLV Combo, the upcoming SNAP® Feline Triple™, SNAP® 4Dx®, SNAP® cPL™, SNAP® Giardia and SNAP® Parvo tests. This new analyzer provides a convenient alternative to visual interpretation of SNAP® kits and will automatically capture the results for the patient’s record and the IDEXX VetLab® report.
For more information, please visit www.idexx.com/snapshot or call IDEXX at 1-800-355-2896.
About IDEXX VetLab® Suite
The IDEXX VetLab Suite is a highly integrated set of veterinary analyzers that provides fast and flexible results on a patient's blood and urine within minutes of the pet visit. Diagnostic capabilities include clinical chemistry, electrolytes, hematology with five-part differential and reticulocytes, endocrinology, blood gases, coagulation, urinalysis and infectious diseases. The IDEXX VetLab® Station, which serves as an information system for the in-house laboratory, uses the power of SmartLink™ technology to integrate results from all the analyzers—including the new Catalyst Dx™ and SNAPshot Dx™ Analyzers—and IDEXX SNAP® point-of-care tests into a single comprehensive and easy-to-use patient report and stores this information in its database for easy future reference and historical results-trending capability.
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice management systems and pharmaceuticals. IDEXX products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 4,500 people and offers products to customers in over 100 countries.
Note Regarding Forward-Looking Statements
This press release contains statements about the Company's business prospects that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management's expectations. Factors that could cause or contribute to such differences include the following: the Company's ability to develop, manufacture, introduce and market new products and enhancements to existing products; the effectiveness of the Company's sales and marketing activities; the Company's ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition and technological change on the markets for the Company's products; the effect of government regulation on the Company's business, including government decisions about whether and when to approve the Company's products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of the Company's products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company's products and services by veterinarians; the Company's ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; disruptions, shortages or pricing changes that affect the Company's purchases of products and materials from third parties, including from sole source suppliers; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company's inventories; the Company's ability to manufacture complex biologic products; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 (PDF, 1.5 MB), in the section captioned "Risk Factors."
Contact: Jennifer Mazjanis, LVT, Senior Chemistry Marketing Manager, 1-207-556-4888, jennifer-mazjanis@idexx.com